Clinical Trials

124 enrolled 17 charts

Brenner Tumor, Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT02298959 2026-04-13

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

DermatologicGastrointestinalGenitourinaryGynecologicSarcoma

59 enrolled

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

6,452 enrolled 2 FDA

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT02466971 2026-04-13

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

450 enrolled 11 charts

Uterine Cervical Neoplasms, Vaginal Neoplasms

NCT02595892 2026-04-13

Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

70 enrolled 23 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02627443 2026-04-13

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

35 enrolled 13 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02834013 2026-04-13

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcoma

818 enrolled

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

NCT02839707 2026-04-13

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2/3 Active not recruiting

444 enrolled 17 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03348631 2026-04-13

Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer

62 enrolled 14 charts

Phase 1/2 Active not recruiting

Ovarian Neoplasms

NCT03393884 2026-04-13

OVATION 2

130 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT03587311 2026-04-13

Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

96 enrolled

Fallopian Tube Endometrioid Adenocarcinoma

NCT03914612 2026-04-13

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

813 enrolled 16 charts 2 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT04034927 2026-04-13

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

61 enrolled 15 charts

Fallopian Tube Neoplasms

NCT04092270 2026-04-13

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

54 enrolled

Phase 1/2 Active not recruiting

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT04287868 2026-04-13

Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies

51 enrolled 16 charts

GastrointestinalGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Oropharyngeal Neoplasms, Rectal Neoplasms

NCT04491942 2026-04-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

BreastGenitourinaryGynecologicOther solid neoplasmThoracic

74 enrolled

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Penile Neoplasms, Triple Negative Breast Neoplasms

NCT04494113 2026-04-13

Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy

Phase EARLY_PHASE1 Active not recruiting

12 enrolled

Endometrial Serous Adenocarcinoma

NCT04553133 2026-04-13

PF-07104091 as a Single Agent and in Combination Therapy

BreastGynecologicThoracic

157 enrolled

Breast Neoplasms, Ovarian Neoplasms, Small Cell Lung Carcinoma

NCT04739800 2026-04-13

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Phase 4 Active not recruiting

120 enrolled 19 charts

GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

NCT05237947 2026-04-13

PRISMA

5,000 enrolled

Human Papillomavirus-Related Cervical Carcinoma

NCT05446298 2026-04-13

PRESERVE-004

58 enrolled

Phase 1/2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05538897 2026-04-13

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

96 enrolled

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

NCT05554367 2026-04-13

Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial

GastrointestinalGynecologic

199 enrolled

Ovarian Neoplasms, Pancreatic Neoplasms

NCT05634499 2026-04-13

EndomERA

30 enrolled

Endometrial Neoplasms

NCT05691504 2026-04-13

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

42 enrolled

GynecologicSarcoma

Carcinosarcoma, Fallopian Tube Neoplasms, Endometrial Neoplasms

NCT06238479 2026-04-13

EXCEED

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

490 enrolled

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Ureteral Neoplasms, Urologic Neoplasms, Triple Negative Breast Neoplasms

NCT05858736 2026-04-09

PRESERVE-009

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

18 enrolled

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03772028 2026-04-08

OVHIPEC-2

538 enrolled

Ovarian Neoplasms

NCT05462717 2026-04-08

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

GastrointestinalGynecologicThoracic

222 enrolled

Appendiceal Neoplasms, Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Intestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Stomach Neoplasms, Thoracic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Carcinoma, Pancreatic Ductal

NCT00579514 2026-04-07

Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients

Phase NA Active not recruiting

21,081 enrolled

BreastGastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms

NCT01287871 2026-04-07

Addressing Stigma in Screening and Diagnostic Delay for Cervical Cancer

Phase NA Active not recruiting

336 enrolled

Cervical Cancer Screening

NCT03937154 2026-04-07

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

BreastGynecologicThoracic

145 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms

NCT04044859 2026-04-07

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

DermatologicGastrointestinalGynecologicHead & NeckThoracic

120 enrolled

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT06003231 2026-04-07

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

GynecologicHead & NeckThoracic

120 enrolled

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT03017131 2026-04-06

Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

9 enrolled